Speakers

Expand/Collapse

Alan Watt
Chief Scientific Officer
Nodthera

Alan has over 30 years of experience in drug discovery and development in both the pharmaceutical and biotechnology sectors. His previous roles include serving as vice president of therapeutics at Bicycle Therapeutics, as chief operating officer and executive vice president of R&D at Trident Pharmaceuticals, and as chief executive officer of Xenovium. Alan formerly led inflammasome discovery at GlaxoSmithKline, where he established the Pattern Recognition Receptor Discovery Performance Unit within GSK’s Immuno-Inflammation Centre of Excellence for Drug Discovery (CEDD). He also previously served as head of drug metabolism and in vivo pharmacology at Merck. Alan holds a Bachelor of Science in chemistry from the University of Southampton, a Ph.D. in drug metabolism from the University of Hertfordshire and an MBA from the Open Business School. He has over 50 peer-reviewed scientific publications.

Day One

Wednesday 30 October 2019

2:30 pm | The Discovery & Development of NT-0167, a Potent, Selective NLRP3 Inflammasome Inhibitor

8:50 am | Chair’s Opening Remarks

Day Two

Thursday 31 October 2019

5:00 pm | Chair’s Closing Remarks

Ariel Feldstein
Professor & Chief, Pediatric Gastroenterology & Founder
UC San Diego & Jecure Therapeutics

Dr. Ariel Feldstein is Chief of the Gastroenterology, Hepatology & Nutrition Division at Rady Children's Hospital-San Diego and a Professor of Pediatrics (with Tenure) at UC San Diego School of Medicine. After graduating from the Univ. of Buenos Aires and completing a postdoctoral program in physiology at the Mayo Clinic, Dr. Feldstein went on to become the Director of Research for the Pediatric Institute at the Cleveland Clinic before moving to San Diego in 2011. Dr. Feldstein has published over 170 peer-reviewed publications, including articles in Nature, Journal of Clinical Investigation, Gastroenterology, Hepatology, Gut, Journal of Biological Chemistry, and Journal of Immunology among others. His research laboratory has provided key evidence regarding the role of cell death, innate immune activation and inflammatory responses driven by Inflammasomes during chronic tissue injury and carcinogenesis.  He is an innovator and an entrepreneur being the founder of two Biotech Companies, Torrey Pines Metabolic Health Labs and Jecure Therapeutics (acquired by Genentech/Roche in 2018).

Day Two

Thursday 31 October 2019

9:00 am | Inflammasome Modulation to Treat NASH & Liver Fibrosis

Changyun Hu
Senior Scientist
Jounce Therapeutics

Changyun Hu, received his Ph.D. in Biochemistry and Molecular Biology from Fudan university, is currently a senior scientist working at the Jounce Therapeutics Inc to develop antibody-mediated immunotherapies for cancer patients since 2016.  After completion of his degree he has studied the role of innate immunity and adaptive immunity in the pathogenesis of autoimmune disease at School of Medicine at Yale University. Using non-obese diabetic mouse as the primary preclinical model, he made significant contribution to understand the etiology of type 1 diabetes.  He was one of the first few researchers that demonstrated the involvement of gut flora in regulating autoimmunity through working on TLR signaling pathway. He was the first few scientists that proposed the T2/MZP B cells as regulatory B cells to control autoimmunity. His preclinical study on B cell depletion therapy was later tested in the clinical trial of rituximab for type 1 diabetes patients. He has published in high impact journals such as Nature, PNAS, Diabetes and Journal of Clinical Investigation. He worked at Antibody Engineering Department at Genentech Inc to focus on in vivo antibody discovery from 2015 to 2016. Dr. Hu is an editorial board member of Austin Journal of Obesity & Metabolic Syndrome, and reviewer for journals including Journal of Immunology and Diabetes. His interests are focused on autoimmune diseases, immune-oncology and other immunological diseases.

Day Two

Thursday 31 October 2019

11:30 am | NLRP3 Inflammasome, Chemotaxis & Autoimmune Disease

Chris Gabel
Vice President, Biology
Nodthera

Chris began his research career as an assistant professor in cell biology at Columbia University studying lysosomal enzyme trafficking. He subsequently transitioned to drug discovery research and spent over 20 combined years seeking to identify novel therapeutics as part of the inflammation drug discovery units at Pfizer and Amgen. While at Pfizer, Chris and his research team pioneered studies aimed at understanding cellular processes involved in regulating posttranslational processing of newly synthesized IL-1β. The lead compound that emerged from this effort was later demonstrated by others to be a selective inhibitor of NLRP3 activation, establishing the drugability of this axis. Chris later spent several years working as an independent consultant, during which time he helped to launch NodThera. Chris received his Bachelor of Science in biochemistry from Iowa State University and his Ph.D. in biochemistry from the University of Washington. He has over 70-peer reviewed publications.  

Day One

Wednesday 30 October 2019

9:30 am | The Discovery & Characterisation of a Novel Chemotype for Enhanced NLRP3 Inflammasome Inhibition & Tissue Penetration

CJ Barnum
Director of Neurosciences
INmune Bio

CJ Barnum is the Director of Neuroscience for INmune Bio, a NASDAQ company (INMB) whose focus is to reprogram the innate immune system to fight disease. Dr. Barnum joined industry after spending more than a decade studying innate immune dysfunction in neurologic disease and is currently leading a biomarker directed program to treat innate immune dysfunction in Alzheimer’s patients.

Day Two

Thursday 31 October 2019

12:00 pm | Approaching Neurodegenerative Disease as an Immunological Disease

Daniel Bachovchin
Assistant Professor
Memorial Sloan Kettering Cancer Center

Dr. Daniel Bachovchin is an Assistant Professor in the Chemical Biology Program at the Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center.  His lab is interested in characterizing the roles that proteases play in cancer and immune system signaling. Dr. Bachovchin received his Ph.D. in 2011 from The Scripps Research Institute under the guidance of Dr. Benjamin F. Cravatt.  From 2011-2015, Dr. Bachovchin was a postdoctoral fellow in Dr. Todd Golub’s laboratory at The Broad Institute.

Day Two

Thursday 31 October 2019

2:00 pm | Activation of the NLRP1 Inflammasome

Davide Povero
Senior Research Scientist, Department of Biochemistry & Molecular Biology, Mayo Clinic
Previous Jecure Therapeutics Employee

Dr. Davide Povero is currently a Senior Research Scientist in the Department of Biochemistry and Molecular Biology at Mayo Clinic Rochester, MN. He received his MSc in Biomedical Sciences and his PhD in Experimental Medicine and Oncology from the University of Torino, Italy. During his graduate training he moved to the US and pursued his training on pathobiology of nonalcoholic steatohepatitis (NASH), liver fibrosis and inflammation at the Cleveland Clinic and at the University of California San Diego in the laboratory of Prof. Ariel Feldstein. After his postgraduate training, he joined early on Jecure Therapeutics, a biotech start-up based in San Diego and acquired by Genentech in November 2018. At Jecure, Dr. Povero worked on cell and in vivo pharmacology of potent and selective inhibitors of NLRP3 for treatment of NASH and liver fibrosis.

Day One

Wednesday 30 October 2019

4:00 pm | Molecular Signals that Activate NLRP3 Inflammasome & Trigger Sterile Inflammation

Erik Hett
Head of Experimental & Chemical Biology
Merck

Dr. Erik Hett received his Ph.D. from Harvard University in the lab of Dr. Eric Rubin, studying protein-protein interactions important for regulating cell division in mycobacteria. His postdoctoral research was conducted in the lab of Dr. Deborah Hung at Harvard, Broad Institute and Massachusetts General Hospital, where he conducted phenotypic high-throughput screens and utilized chemoproteomics for target ID. He previously was a chemical biologist in the MedChem Department at Pfizer and led a chemical biology team in the mechanisms and pathways group at Biogen. He is currently the Head of Experimental and Chemical Biology at the Merck Exploratory Science Center in Cambridge, MA.

Day One

Wednesday 30 October 2019

12:00 pm | A Chemical Approach to Map Protein Interactions

Hao Wu
Professor
Harvard Medical School

Hao Wu, Ph.D., received her pre-medical training at Peking University from 1982 to 1985 and studied Medicine at Peking Union Medical College from 1985 to 1988. She obtained her Ph.D. degree in Biochemistry from Purdue University in 1992, working in the laboratory of Professor Michael Rossmann. After performing postdoctoral training at Columbia University in the laboratory of Professor Wayne Hendrickson, she became an Assistant Professor at Weill Cornell Medical College in 1997 and was promoted to Professor in 2003. In 2012, Dr. Wu moved to Harvard Medical School as the Asa and Patricia Springer Professor of Pediatrics and of Biological Chemistry and Molecular Pharmacology, and as the Senior Investigator in the Program in Cellular and Molecular Medicine of Boston Children’s Hospital. Dr. Wu has received a number of honors, including the Howard Hughes Medical Institute pre-doctoral fellowship, the Aaron Diamond postdoctoral fellowship, the Pew Scholar award, the Rita Allen Scholar award, New York Mayor’s Award for Excellence in Science and Technology, the Margaret Dayhoff Memorial Award from the Biophysical Society, Purdue University Distinguished Science Alumni Award, Dorothy Crowfoot Hodgkin Award from the Protein Society and Milstein Award from the International Cytokine and Interferon Society. Dr. Wu serves on the Scientific Advisory Council of the Cancer Research Institute and the Editorial Board of Cancer Cell, and is an elected member of the US National Academy of Sciences.

Day One

Wednesday 30 October 2019

12:30 pm | Structure of The NLRP3-NEK7 Complex & the Mechanism of NLRP3 Activation

Humayun Sharif
Research Fellow
Harvard Medical School

I am an independent biomedical researcher with a focus on elucidating structure driven mechanisms of disease associated proteins. A visionary with extensive research experience in diverse geographical locations (Asia, Europe and North America) over the past decade. I am a fast learner and adapt quickly to new work environments and working with people of diverse backgrounds.

John Wing
Senior Medical Science Liaison
PTC Therapeutics

John Wing is currently a Senior Medical Science Liaison at PTC Therapeutics, where he is part of an MSL team that engages with experts within the rare disease space to support the development and dissemination of clinical data and other scientific information. He originally joined PTC Therapeutics as a consultant and then Director of Medical Education and Training within the Global Scientific Affairs group. Just prior, John was a Senior Consultant for Innovara where he supported training and development initiatives for Medical Affairs teams across the globe. At Shire Pharmaceuticals, John was the Director of Training and Effectiveness for Global Medical Affairs. In this role, he supported the development and delivery of training and development programs for Medical Science Liaisons, Medical Affairs Specialists and Medical Directors in Shire’s Rare Disease Business Unit. The purpose of these programs was to support the scientific educational and professional development of a diverse global Medical Affairs team. John received his Ph.D. in Molecular and Cellular Biology from the University of Massachusetts and has held a variety of positions in both the Biotech and Pharmaceutical industries as well as in Academia. At Eyetech Pharmaceuticals, he led a team of assay development scientists whose main role was to support the development of Macugen, an FDA approved drug for Age Related Macular Degeneration. At Phylos, he led a team to support the continued development of the company’s patented display technology. After Eyetech Pharmaceuticals, John joined the Biology department at Boston College as a Visiting Assistant Professor. While at B.C., he acted as the principal investigator for a molecular genetics lab consisting of graduate and undergraduate students performing independent theses research. He also developed and taught a variety of lecture courses and laboratory courses in the areas of Genetics and Molecular Biology. John currently holds an Adjunct faculty position at Framingham State University, where he supports a Master’s Program in Biotechnology for current professionals.

Day Two

Thursday 31 October 2019

4:30 pm | Mastermind Session: Discussing the Potential of Inflammasome Therapeutics in Combination

4:00 pm | The Immune Response in Duchenne Muscular Dystrophy: Current Therapeutic Approaches & Potential Translational Opportunities

Juan Pablo De Rivero Vaccari
Research Assistant Professor
University of Miami Miller School of Medicine

Dr. de Rivero Vaccari is currently a Research Assistant Professor in the Department of Neurological Surgery & The Miami Project to Cure Paralysis. He is also a Distinguished Faculty member of the Center for Cognitive Neuroscience and Aging at the University of Miami Miller School of Medicine. He has studied the innate immune response for 15 years and was the first to show the involvement of the inflammasome complex in vivo in a sterile event, particularly after spinal cord injury.  Dr. de Rivero Vaccari has also contributed to studies of the innate immune response following brain injury, stroke, aging, multiple sclerosis, depression, sciatic nerve pain, Alzheimer’s disease, male infertility, male pattern baldness, wound healing, disc degeneration and corneal degeneration. In addition, he has published biomarker research on stroke, spinal cord and brain traumatic injury, multiple sclerosis, depression and mild cognitive impairment. Dr. de Rivero Vaccari graduated Summa Cum Laude with a B.S. in Biology from Florida International University where he was inducted into The Phi Beta Kappa Honor Society (2004). He then pursued his Ph.D. in Physiology & Biophysics at the University of Miami in the laboratory of Dr. Robert W. Keane (2007) and his post-doctoral fellowship in Neurotrauma at The Miami Project to Cure Paralysis in the laboratory of Dr. W. Dalton Dietrich (2010). In addition, Dr. de Rivero Vaccari has trained on Biomarker Science at the Harvard Clinical and Translational Science Center and on Computational Immunology at the Santa Fe Institute. He is currently pursuing a Master of Science degree in Business Analytics at the Miami Business School of the University of Miami. Dr. de Rivero Vaccari is a co-founder and managing member of InflamaCORE, LLC; an Associate Editor for the Journal Frontiers in Molecular Neuroscience, and a Scientific Advisory Board Member for ZyVersa Therapeutics. He has served as an ad hoc reviewer for over 60 different scientific journals, has co-author over 50 peer-reviewed articles, and his work has been cited over 3,000 times. Dr. de Rivero Vaccari has filed 13 patents in the areas of inflammasome therapeutics and diagnostics.

Day Two

Thursday 31 October 2019

3:00 pm | Inflammasome Proteins as Biomarkers

Kate Fitzgerald
Principal Investigator
Umass Medical School

Dr. Fitzgerald is Professor of Medicine, Director of the Program in Innate Immunity and the Worcester Foundation Chair in Biomedical Sciences at the University of Massachusetts Medical School, Worcester, MA, USA where she has been since 2001. She received her B.Sc. in Biochemistry in 1995 from University College Cork, Ireland and her PhD in Biochemistry in 1999 from Trinity College Dublin, Ireland. Dr. Fitzgerald directs an internationally recognized laboratory focused on understanding the molecular mechanisms controlling the inflammatory response in both health and disease. Her group is interested in determining how the immune system distinguishes friend from foe in order to protect the host from infection and avoid damaging inflammatory responses that lead to a wide range of inflammatory diseases. Her lab uses multifaceted approaches including immunology, biochemistry, molecular biology and genetics to understand the role of inflammasomes, nucleic acid sensing pathways and long non-coding RNAs in the inflammatory response. The long-term goal of her work is to determine how inappropriate activation of innate immunity underlies the pathogenesis of infectious, inflammatory and autoimmune diseases in humans. Dr. Fitzgerald has received several awards including a MERIT award from the NIH, the Saint Patrick’s Day Medal, from the Irish Government and Science Foundation Ireland, the Milstein Award for Excellence in Interferon and Cytokine research (from the International Cytokine and Interferon Society), the Eli Lilly and Company Elanco Research Award (from the American Society of Microbiology) and the BD-Biosciences Investigator Award (from the American Association of Immunologists). She is ranked amongst the top 1% most Cited researchers for Immunology for the last five years (Thompson Reuters, 2014, 2015, 2016, 2017, 2018) and is currently President elect of the International Cytokine and Interferon Society (Fall 2019 term).

Day One

Wednesday 30 October 2019

10:00 am | Inflammasomes in Infection & Inflammation

Marcelo Hill
Chief Scientific Officer & Founder
ARDAN ImmunoPharma

Marcelo Hill is MD (Universidad de la Republica, Uruguay) and PhD in immunology (Université de Nantes, France). He is the Director of the FOCIS Center of Excellence “Center for Translational Immunology” at Institut Pasteur Montevideo. Dr Hill is Associate Professor of immunology at Universidad de la Republica. He is founder and CSO of ARDAN Immuno Pharma.

Day Two

Thursday 31 October 2019

11:00 am | Targeting Ion Channels to Trigger Inflammasome-Dependent Tumor Immunity

Matthew Havrda
Assistant Professor of Molecular & Systems Biology
Dartmouth School of Medicine

Dr. Havrda is a neurobiologist interested in understanding the molecular basis of brain disorders, especially Parkinson’s disease and its various pathologic manifestations. He received his Ph.D. from the Graduate School of Biomedical Science and Engineering at the University of Maine and is currently an Assistant Professor in Molecular and Systems Biology at the Geisel School of Medicine at Dartmouth. Dr. Havrda’s research garnered prestigious young investigator awards including the Ruth L. Kirschstein National Research Service Award and a K12 Award for Clinical and Translational Research. Dr. Havrda’s laboratory continues to focus on characterizing the molecular basis of neuroinflammation during the progression of Parkinson’s disease both in cellular and animal models as well as in biofluids and post-mortem tissues obtained from Parkinson’s patients. Inflammasome research conducted in Dr. Havrda’s lab is supported by from the Michael J. Fox Foundation, the National Institute for Environmental Health Sciences, and the National Institute on Aging.

Day Two

Thursday 31 October 2019

9:30 am | Characterizing NLRP3 in Parkinson’s Disease

Rachel Mak’Anyengo
Product Manager 
Novarits

Rachel is an accomplished Molecular Immunologist with comprehensive experience in Oncology, Immunology, Inflammatory Diseases, Immune-related Diseases, and Cardio-Metabolic. Being a detail-oriented and strategic thinking professional with strong problem solving skills, I apply my extensive knowledge and experience to successfully contribute to different disease areas. My strong educational background and comprehensive experience as a scientist has given me a clear appreciation of how theory translates in tackling different therapeutic areas. My goal is to be a part of innovation in healthcare, and accomplish goals in a team, while mutually supporting one another.

Day One

Wednesday 30 October 2019

Rebecca Coll
Principle Investigator,
Wellcome-Wolfson Institute for Experimental Medicine
Queen's University Belfast

Dr Rebecca Coll joined the Wellcome-Wolfson Institute for Experimental Medicine at Queen’s University Belfast as a Lecturer in Immunobiology in 2019, following her postdoctoral work at the University of Queensland where she studied innate immunity and novel anti-inflammatory molecules. Rebecca received her PhD in Immunology in 2013 in Professor Luke O’Neill’s lab at Trinity College Dublin and moved to Associate Professor Kate Schroder’s group at the Institute for Molecular Bioscience in UQ in 2014. Rebecca's research is focused on inflammasomes – protein complexes at the heart of inflammation and disease – and how these complexes can be targeted therapeutically to prevent damaging inflammation. Rebecca led the biological characterisation of MCC950, a small molecule inhibitor of the NLRP3 inflammasome and an exciting prospect as a new therapy for treating patients with NLRP3-mediated diseases. In 2016 Rebecca was awarded the Research Australia Discovery Award for her work on NLRP3 inhibitors.

Day One

Wednesday 30 October 2019

9:00 am | Targeting the NLRP3 Inflammasome for the Treatment of Inflammatory Diseases

Russell Wyborski 
Associate Director, Technical Operations
BioMotiv

Dr. Russell J. Wyborski has over 25 years of drug discovery and product development experience at Pfizer and Avon Products. His research experience includes work in the Neuroscience, Cardiovascular, Inflammation, and Skin Biology Therapeutic Areas. His experience at Pfizer included both small molecule and antibody approaches for therapeutic agents. His focus in these areas has been the understanding of the regulation of gene expression specifically focused on nuclear hormone receptors. He holds several patents. Dr. Wyborski joined BioMotiv in August 2016. Since that time, he was responsible for the scientific diligence review that led to the formation of Koutif Therapeutics in September 2017. As the Project Operations Director for Koutif Therapeutics, he has been responsible for leading the company through the IND filing process and subsequent planning for the initiation of the Phase Ia Clinical Trial scheduled for 4Q19. Dr. Wyborski received his Ph.D. in Biochemistry from Indiana University. His research on the kinetics of glucagon receptor binding resulted in being awarded the Outstanding Graduate Student Award from the Medical Science Program in the year his graduate degree was awarded. He completed a Postdoctoral Fellowship in Neurobiology at the Washington University at St. Louis Medical School focusing on the regulation of the glutamic acid decarboxylase gene which is the enzyme responsible for the production of the primary inhibitory neurotransmitter GABA. He was awarded a B.S. in Chemistry from the University of Notre Dame.

Day Two

Thursday 31 October 2019

8:30 am | Fbx03 Inhibitor KT-1002 for the Treatment of Inflammatory Bowel Disease

Steve Glover
Co-founder & Chief Executive Officer
ZyVersa Therapeutics

Mr. Glover has over 35 years of executive, operational, and commercial leadership experience in biopharmaceuticals and life sciences, encompassing Fortune 100, start up, and entrepreneurial companies. His transaction experience totals over $10 billion, covering more than 25 transactions with several international companies and major U.S. banks. Mr. Glover’s demonstrated success in leading public companies, increasing market capitalization, increasing shareholder value and taking companies public is highlighted below in his accomplishments at ZyVersa, Coherus Biosciences, Insmed, and Andrx. ZyVersa is a clinical stage company leveraging advanced proprietary technologies to develop best-in-class drugs for patients with rare diseases. The lead asset is Phase 2a ready VAR 200, hydroxypropyl beta cyclodextrin (HPβCD) for treatment of focal segmental glomerulosclerosis (FSGS). With our pre-clinical inflammasome programs we are transforming immunotherapy to improve the lives of patients with serious diseases. We focus on developing compounds that precisely target the innate immune system, the body’s first line of immunological response. Looking upstream of the adaptive immune system to focus on developing drugs that target the innate immune system, the body’s first line of immunological response and the master regulator of subsequent immune activity. Innate immune biology offers a multitude of potential drug targets and pathways across several therapeutic areas. As former Co-founder and Chief Business Officer of Coherus Biosciences, Mr. Glover’s strategic focus on key product development initiatives and partnership opportunities. The initial public offering in 2014 was priced at $85 million and the IPO was led by JP Morgan, Credit Swiss and Cowen. As President of Insmed, a NASDAQ public company, Mr. Glover’s strategic insights led to creation of Insmed’s biosimilar business unit. Within two years, Mr. Glover was able to leverage clinical advancement of several biosimilar products to achieve divestiture of the business to Merck, a $130 Million cash deal. As President of Insmed Incorporated, Mr. Glover’s negotiations for a high value, late stage asset led to the merger of Insmed and Transave, significantly increasing shareholder value. Imsmed currently has a market cap of $2.4B As Senior Vice President and General Manager at Andrx Laboratories and Andrx Therapeutics, divisions of Andrx Corporation, Mr. Glover was responsible for business strategy and operations. Andrx Labs developed and marketed products in metabolic diseases and Men's Health. Andrx Therapeutics developed and marked high value, specialized sustained-release products, and served as a contract manufacturer. Mr. Glover was the executive in charge for the sale of Andrx. Andrx , a NASDAQ company was acquired by Watson for $1.9 Billion in 2006.

Day One

Wednesday 30 October 2019

2:00 pm | How Much Time & Effort Should any Company be Spending on Preclinical Models

Matt Cooper
Chief Executive Officer & Co-Founder
Inflazome

Prof. Cooper is co-founder and CEO of Inflazome, co-founder and Director of Defensin Therapeutics, Affiliate Prof. in Biochemistry at Trinity College Dublin, Prof. Chemical Biology at the University of Queensland, Director of the Centre for Open Antimicrobial Drug Discovery (CO-ADD) and the IMB Centre for Superbug Solutions. He was the founder and Managing Director of Cambridge Medical Innovations (now part of Abbot) and CSO and co-founder of Akubio. He has worked in tools companies, diagnostics and therapeutics and consulted widely in the areas of drug screening and drug design, infectious diseases, innate immunity and the microbiome with AdProTech, Alere, Apax Capital Partners, AstraZeneca, Cambridge Antibody Technology, DeNovo Pharmaceuticals, Ellume, GE Healthcare, Heptares, Ionian Technologies, Inverness Medical Australia, NxP Semiconductor, OSI Pharmaceuticals, Pfizer, Protein Mechanics, Respirio, Science Foundation Ireland, Sense Proteomics/Procognia and Solexa (now Ilumina).  

Day Two

Thursday 31 October 2019

8:00 am | Pharmacology Inhibition of the NLRP3 Inflammasome

Bernat Baeza-Raja
Senior Scientist
Second Genome

Bernat’s work specifically focuses on developing novel therapeutics from the gut microbiome for the treatment of metabolic diseases. Additionally, his work is also focused on preclinical work and development of inflammasome activity modulators for the treatment of NASH.

Day Two

Thursday 31 October 2019

2:30 pm | Targeting the Inflammasome through P2X7 receptor & Its Potential Implications for NASH Therapy